The company's EPS and revenue growth don't match its share price decline, hinting at possible over-hype or other factors. Last year's performance suggests unresolved issues. Investors should consider financial health and potential risks before investing.
The company's P/E ratio aligns with moderate growth expectations, yet the market is predicted to grow by 16% annually, a more appealing prospect. Investors holding onto their stock may face future disappointment if the P/E aligns with the growth outlook.
The company's consistent reinvestment of capital at increasing rates of return is promising. Despite the stock's past decline, ongoing trends may offer investment opportunities. Further research into the company and its future trends is advised.
Despite appearing high, the P/E ratio's justification is debatable. With subpar growth estimates compared to the market, its sustainability is uncertain, posing significant risks for current shareholders and potential overpayment for novices.
While offloading of shares by insiders could raise concerns, the comparatively high selling price relative to the current price offers some comfort. However, there have been no recent insider transactions, which could be a less encouraging sign for potential investors.
Shandong Weigao Group's dividends are considered sustainable given their coverage by profits and cash flow. The company's potential for more dividend increases is indicated by its reasonable payout ratio and earnings growth. Analysts commend its consistent earnings growth and efficient cash flow use.
SHANDONG WEIGAO GPに関するコメント
DBS: China Healthcare Sector – Pharmaceutical Packaging
$微創医療科学(00853.HK)$$山東威高(01066.HK)$$石薬集団(01093.HK)$$国薬(01099.HK)$$鳳凰医療(01515.HK)$$康臣薬業(01681.HK)$$春立医療(01858.HK)$$環球医療(02666.HK)$$復宏漢霖(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$百済神州(06160.HK)$
DBS: Shandong Weigao Group Medical Polymer Co Ltd – Buy Target Price HK$14.50
$山東威高(01066.HK)$
DBS: China Biotech Sector
$百済神州(06160.HK)$$石薬集団(01093.HK)$$復宏漢霖(02696.HK)$$微創医療科学(00853.HK)$$山東威高(01066.HK)$$国薬(01099.HK)$$鳳凰医療(01515.HK)$$康臣薬業(01681.HK)$$春立医療(01858.HK)$$環球医療(02666.HK)$$復宏漢霖(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$百済神州(06160.HK)$
まだコメントはありません